NEWSPACE-CAPITAL
15.12.2022 08:31:42 CET | Business Wire | Press release
NewSpace Capital announces the first closing of its space-focused growth fund at €105M and a €15M lead investment in Cailabs’ series C investment round.
NewSpace Capital is a Luxembourg-based private equity fund dedicated to space-focused technology investments. The firm targets growth-equity opportunities in downstream applications and supply chain segments of the space market. NewSpace Capital has a global investment outlook with its main focus on Europe and the US. The closing was led by a cornerstone investment from Archean Capital Partners, a US fund dedicated to investing in emerging fund managers with specialized sector and operational experience. Other investors include corporates, financial institutions and family offices.
NewSpace Capital is also announcing a €15M investment in Cailabs, a French deep-tech company enabling revolutionary photonic solutions for industrial and communication applications. NewSpace Capital is the lead investor in Cailabs’ €26M series C financing round.
The fund’s other investments to date include ICEYE, which owns and operates the world’s largest constellation of synthetic aperture radar (SAR) satellites, and Kayrros, a climate-tech data analytics company that recently won the Financial Times’ prestigious 2022 Tech Champions Award.
Rob Lazaroff, Co-Portfolio Manager of Archean Capital said, “There are an increasing number of companies reaching the commercial stage in space, many of which are ready for growth stage capital. The NewSpace Capital team has an ideal mix of technical and commercial expertise to identify and select the best space companies, and help them achieve their growth plans.”
“We are very selective in backing new funds and we are willing to wait for the right combination of team, strategy and market opportunity. NewSpace Capital has an amazing network within the space ecosystem that makes them a preferred partner to companies like Cailabs. We are thrilled to support the team as they build NewSpace Capital into the next market leading private equity firm” said Chris Keller, Co-Portfolio Manager of Archean Capital.
“The space ecosystem becomes a backbone for economic and social change. We are a value investor in companies that enable this process with new technologies and capabilities. NewSpace Capital allows its LPs to tap into the growth segment of a €300-billion industry spanning Earth observation, communication and data analytics. We are excited to partner with Archean, whose team brings a wealth of knowledge and a unique partnership approach” said Bogdan Gogulan, CEO and Managing Partner of NewSpace Capital.
NewSpace Capital is a conduit to enable corporates and financial investors to achieve net-zero targets: “The space industry is critical to solving global ESG challenges. In addition to identifying, measuring, and mitigating the environmental impact of existent economic activity that can be done from space on a global scale, space infrastructure and space-enabled services also create a completely new way of operating for traditional industries, that allows the transition to a more efficient and net-zero economy,” said Felix von Schubert, Executive Chairman of NewSpace Capital.
About NewSpace Capital
NewSpace Capital is a global space-focused, growth-stage fund operated by a team that together has more than 150 years of investment, commercial and technical experience in the space and private equity industries. Based in Luxembourg, the fund provides growth capital to companies with a technological edge and leading market position in the supply chain and applications segments of the rapidly developing space ecosystem. To learn more visit www.newspace.capital
About Archean Capital Partners
Archean Capital Partners provides strategic anchor capital to newly-formed private equity firms. Archean was established in 2017 by Veritable, L.P. and Moelis Asset Management to provide initial limited partner capital and value-added support to highly qualified emerging managers. Archean is focused on opportunities in such specialties as buyout, growth, restructuring and turnaround. To learn more visit www.archeancapital.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom